ArriVent BioPharma, Inc. Share Price & Technical Analysis
AVBP · $31.49 (+5.74%)
Healthcare / Biotechnology
$31.49
+5.74%
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutatio…
Price chart
Seasonality
Jun has 1 positive and 2 negative years (last 3 years shown)
-1% return in Jun, -3% avg return in past 3 year Jun month.
48% return in 2026, 8% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 11% | 3% | 3% | 33% | -2% | -1% | – | – | – | – | – | – | 48% |
| 25 | 5% | -15% | -21% | 17% | 0% | 1% | -10% | -1% | -3% | 2% | 24% | -11% | -10% |
| 24 | -10% | 0% | -15% | -8% | 18% | -7% | 21% | 21% | -13% | 27% | 2% | -11% | 26% |
Monthly return % by calendar month · historical pattern, not a forecast
Neutral · Strong · Strong
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$1.33B
P/E ratio
—
52W high
$32.14
52W low
$16.10
Volume
1,03,951
Beta
1.52
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹34,400
Abbott Laboratories Cede…
₹32,740
Eli Lilly And Company Ce…
₹28,720
Unitedhealth Group Inc C…
₹17,140
Elevance Health Inc
₹6,770
Frequently asked questions
- What is ArriVent BioPharma, Inc. share price today?
- ArriVent BioPharma, Inc. (AVBP) last traded around $31.49 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does AVBP have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for AVBP. Download the app for real-time alerts.
- How can I analyze ArriVent BioPharma, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.